VK2735 is a dual GIP and GLP-1 receptor agonist under investigation for weight management in adults, including those with type 2 diabetes mellitus. It is being evaluated in both injectable and oral formulations across clinical trials.
Investigational. Multiple Phase 3 trials active or not yet recruiting (SUNRISE 1, SUNRISE 2, VANQUISH 2, and others); Phase 2 trials completed; not FDA-approved.
Last reviewed October 13, 2026
The calculator takes vial mass, BAC water volume and your target dose, and returns the exact draw on a U-40, U-50 or U-100 insulin syringe. It does the arithmetic; it does not suggest what the dose should be.
Open the reconstitution calculator →